Mandate

Vinge advises Fidelio Capital in the divestment of a minority stake in Odevo to CVC Capital Partners

Vinge has advised Fidelio Capital (“Fidelio”) and the other shareholders of Odevo Group (“Odevo”) in connection with the divestment of a minority shareholding to funds controlled by CVC Capital Partners (“CVC”). Fidelio, the existing management team and other minority shareholders of Odevo will retain a majority holding in the company.

Odevo has built an organisation which, supported by a bespoke tech-platform, helps residential property owners manage all aspects of their building, ranging from accounting, administration, invoicing and on-site services to renovations. The company was founded in Sweden in 2018 by the investment firm Fidelio and the current management team. Through organic growth and joining forces with more than 50 successful entrepreneurs across Europe and USA, Odevo has expanded the business more than 50x, now managing 1.4 million homes with more than 7,000 employees and an annual turnover of EUR 650 million. By welcoming CVC to the group of investors, Odevo takes yet another step on its international growth journey.

The transaction is subject to applicable regulatory and antitrust approvals.

Vinge’s team consisted of Jonas Bergström, Johanna Wiberg, Anna Jonsson, Elsie Nassar, Amanda Steen, Philip Moré, Lovisa Jonassen and Matilda Hamner (M&A), Nils Unckel and Anton Sjökvist (Financial Regulatory), Sebastian Örndahl and Alva Chambert (EU, Competition and Regulatory), Mathilda Persson, Jolene Reimerson and Siri Blomberg (Commercial Agreements, IT and GDPR), Rebecka Målquist (Intellectual Property), Mia Falk and Gulestan Ali (Compliance), Emelie Schoning, Emy Rydén, Gabriella Balbo and Ottilia Pettersson (Transaction Support Coordinators).

Read the client’s press release here.

Related

Vinge has advised Orexo in connection with the divestment of the US rights to Zubsolv

Vinge has advised Orexo in relation to Swedish law in connection with the divestment of the US rights to Zubsolv to Dexcel Pharma USA.
January 14, 2026

Vinge advises Revivo Group on acquisition of Haapanen

Revivo Group, a comprehensive provider of qualified surface treatment services, has acquired Haapanen, a well-established Finnish specialist company.
January 14, 2026

Vinge advises Morrow Bank in connection with cross-border merger and list change from Oslo Børs to Nasdaq Stockholm

Vinge has advised Morrow Bank in connection with its reverse cross-border merger, whereby Morrow Bank AB is taking over Morrow Bank ASA. The Norwegian bank was previously listed on the Oslo Stock Exchange which was today transferred to Nasdaq Stockholm. Vinge has previously assisted Morrow Bank in obtaining a Swedish banking licence.
January 12, 2026